Arne Kolstad

Oslo University Hospital — Norway

Medicine · Health Sciences

41h-index7.6kcitations228works6.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(161), CAR-T cell therapy research(56), Chronic Lymphocytic Leukemia Research(42), Immune Cell Function and Interaction(38), Cancer Immunotherapy and Biomarkers(33)

Publications228 total

POSTER: IBCL-1066 ELARA Phase 2 Clinical Outcomes for Tisagenlecleucel in Patients With High-Risk Relapsed/Refractory Follicular Lymphoma: 4-Year Update
Clinical Lymphoma Myeloma & Leukemia·2025
IBCL-1066: ELARA Phase 2 Clinical Outcomes for Tisagenlecleucel in Patients With High-Risk Relapsed/Refractory Follicular Lymphoma: 4-Year Update
Clinical Lymphoma Myeloma & Leukemia·2025
836 | MOSUNETUZUMAB FOR EARLY RELAPSE OF FOLLICULAR LYMPHOMA IN THE NORDIC COUNTRIES (MERLIN)
Hematological Oncology·2025Open Access
138 | PHASE 2 ELARA TRIAL 4‐YEAR UPDATE: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH‐RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)
Hematological Oncology·2025· 1 citedOpen Access
Exploring the Prognostic Potential of circSCORE in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Genes·2025Open Access
Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma
Blood Advances·2025· 7 citedOpen Access
Long-term trends in the clinical management and outcomes of patients with gastroesophageal cancer in Norway
Acta Oncologica·2025· 1 citedOpen Access
Allogeneic stem cell transplantation for patients with lymphoma 2011–21
Tidsskrift for Den norske legeforening·2025· 1 citedOpen Access
Circulating Tumor DNA Determinants of Response and Outcome in Relapsed/Refractory Mantle Cell Lymphoma
2024Open Access
1459P Long-term management and outcomes in gastroesophageal cancer in Norway
Annals of Oncology·2024Open Access
IBCL-271 Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow-Up
Clinical Lymphoma Myeloma & Leukemia·2024
Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow- Up
Clinical Lymphoma Myeloma & Leukemia·2024Open Access
MetaGate: Interactive analysis of high-dimensional cytometry data with metadata integration
Patterns·2024· 2 citedOpen Access
Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up
Transplantation and Cellular Therapy·2024· 2 cited
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
Blood·2024· 82 citedOpen Access
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial
Blood Advances·2023· 18 citedOpen Access
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma
Blood Advances·2023· 24 citedOpen Access
Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up
Blood·2023· 10 cited
MetaGate: Interactive Analysis of High-Dimensional Cytometry Data with Meta Data Integration
2023Open Access
POSTER: CT-564 ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL)
Clinical Lymphoma Myeloma & Leukemia·2023
page 1 of 12Next →

Frequent Co-authors

Mats Jerkeman(17), Jan Delabie(16), Christian H. Geisler(14), Lone Bredo Pedersen(14), Harald Holte(14), Riikka Räty(13), Kirsten Grønbæk(12), Anna Laurell(11), Grete F. Lauritzsen(11), Christer Sundström(11), Elisabeth Ralfkiær(9), Mats Ehinger(9), Herman Nilsson‐Ehle(8), Peter de Nully Brown(8), Erkki Elonen(8), Christian Winther Eskelund(8), Mikael Eriksson(7), Eva Kimby(7), Outi Kuittinen(7), June H. Myklebust(7)